Exelixis (EXEL)
(Delayed Data from NSDQ)
$22.40 USD
-0.15 (-0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXEL 22.40 -0.15(-0.67%)
Will EXEL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXEL
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Exelixis (EXEL) Down 6.6% Since Last Earnings Report: Can It Rebound?
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) International Revenue Performance Explored
Other News for EXEL
Exelixis Moves Up In Market Cap Rank, Passing Paramount Global
Interesting EXEL Put And Call Options For February 2025
Insider Sale: Director Jack Wyszomierski Sells Shares of Exelixis Inc (EXEL)
Exelixis treatment of pancreatic neuroendocrine tumors granted orphan status
Exelixis Breaks Above 200-Day Moving Average - Bullish for EXEL